

In the Claims:

Please cancel claims 2-65 without prejudice.

Please add the following new claims 66 to 77:

66. (New) A modified annexin suitable for direct radiolabeling, comprising an annexin modified to provide an accessible sulfhydryl group which is capable of participating in the complexation of a radionuclide.

67. (New) The modified annexin of claim 66, wherein the modification of the annexin comprises an amino acid extension at the N-terminus, said amino acid extension comprising the accessible sulfhydryl group.

68. (New) The modified annexin of claim 67, wherein the sulfhydryl group is within ten amino acids from the N-terminus.

69. (New) The modified annexin of claim 67, wherein the amino acid extension further comprises glycine.

70. (New) The modified annexin of claim 67, wherein the accessible sulfhydryl group is provided by cysteine.

71. (New) The modified annexin of claim 70, wherein the amino acid extension further comprises glycine.

72. (New) The modified annexin of claim 67, wherein the annexin is annexin

V.

73. (New) ~~The~~ modified annexin of any one of claims 66-72, wherein the modified annexin further comprises a radionuclide complexed directly to the modified annexin.

*Sub C*  
74. (New) The modified annexin of claim 73, wherein the radionuclide is a diagnostic radionuclide.

*BZ*  
75. (New) The modified annexin of claim 73, wherein the radionuclide is F-18, Cu-64, Cu-67, Re-186, Re-188, Pd-100, Pd-109, Bi-212, Pb-212, Ga-67, Ga-68, Tc-99m, Tc-94, Ru-95, Ru-105, Rh-99, Rh-105, In-111, I-123, I-125, Sm-153, Lu-177, Lu-170, Pt-189, Pt-193, Au-199 or Hg-197.

76. (New) The modified annexin of claim 75, wherein the radionuclide is Cu-64, Cu-67, Re-186, Re-188, Pd-100, Pd-109, Bi-212, Pb-212, Ga-67, Ga-68, Tc-99m, Tc-94, Ru-95, Ru-105, Rh-99, Rh-105 or In-111.

77. (New) The modified annexin of claim 76, wherein the radionuclide is Tc-99m.